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Abstract To study effectiveness of surgery and watchful
waiting in localized laryngeal amyloidosis, retrospective
case series. This retrospective study comprises all con-
secutive patients with localized laryngeal amyloidosis
surgically treated in a tertiary hospital between 1994 and
February 2016. Recurrence rate, revision surgery, pro-
gression to systemic amyloidosis, and changes in voice
were monitored yearly. Eighteen patients were included.
Seven women and eleven men had a median age 50 years
(range 21–77 years) and median follow-up 6.4 years
(2.4–17 years). Amyloid was located in subglottis (5),
glottis (8), false vocal folds (8) and other supraglottic areas
(5), in more than one laryngeal region (13) and bilaterally
(12). Cold steel excision was used at the glottis; CO2 laser
excision, sometimes assisted by microdebrider, at other
laryngeal areas. Eleven patients needed revision surgery,
ten within the first 4 years after surgical treatment. One
patient needed his first revision surgery after 11 years. Five
patients needed a second revision within 6 years after ini-
tial diagnosis. Two patients needed a third revision. Indi-
cations for first revision surgery were progression (8) with
dysphonia (7), dyspnea (2), dysphagia (1), exclusion of
malignancy (1), and aphonia (1). No patient developed
systemic amyloidosis during follow-up. Although local
progression of amyloid necessitates revision surgery once
or twice in the first 4–6 years, progression slows down
thereafter. Late progression, however, remains possible.
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Introduction
Localized laryngeal amyloidosis is a benign tumorous disease
of the laryngeal region. It consists of amorphous extracellular
deposits of AL amyloid fibrils. The AL amyloid is derived
from immunoglobulin light chains produced by clonal plasma
cells nearby [1]. Localized amyloidosis differs from systemic
amyloidosis. In systemic amyloidosis, the soluble precursor
protein is produced elsewhere in the body (e.g., liver or bone
marrow), released into the circulation and deposited as
insoluble amyloid fibrils throughout the body [2]. Although
rare, laryngeal amyloidosis can be a disease manifestation of
systemic AL amyloidosis [3, 4] or of systemic AApoAI
amyloidosis [5]. (The type of amyloid is designated as a
capital A followed by the characteristic precursor protein [2];
e.g., AL amyloidosis is derived from j or k immunoglobulin
light chains and hereditary type AApoAI amyloidosis from
mutated apolipoprotein AI [2]). Therefore, in the clinical
approach of laryngeal amyloidosis, investigations are direc-
ted to make systemic amyloidosis highly unlikely before
concluding localized laryngeal amyloidosis [3].
Aim of effective therapy of localized laryngeal amy-
loidosis is to obtain a long disease-free interval with
preservation of a good voice, of normal swallowing, and
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absence of dyspnea. Therapeutic options are various
modalities of surgery [3, 6–12]. In rare cases, irradiation
has been advocated [13, 14]. In 2004 we proposed a ther-
apeutic strategy of suspension microlaryngoscopy guided
both by symptoms (e.g., dysphonia or dyspnea) and signs
(relevant stenosis) [3]. Complete excision is preferred.
Debulking of the amyloid deposits is only performed if
radical excision would increase the risk of scarring, dys-
phonia, or dysphagia. The surgical modalities are adapted
to the localization; cold steel excision is used for precise
work in critical anatomic sites such as the true vocal cords
or in case of small deposits. CO2 laser and microdebrider
are used in other parts of the larynx or in bulky amyloid. If
complete excision proved to be impossible without high
morbidity, patients were followed on a yearly basis.
Aim of this study was to investigate the long-term effec-
tiveness of our approach in localized laryngeal amyloidosis in
terms of disease progression, recurrence rate after surgery,
progression to systemic amyloidosis and postoperative voice
characteristics 10 years after our initial study [3].
Materials and methods
Study design, setting and patient selection
This longitudinal observational cohort study comprised all
consecutive patients with localized laryngeal amyloidosis
referred to our tertiary hospital between 1994 and February
2016. All patients were included who presented with
localized laryngeal amyloidosis and were treated with
surgery. Excluded were patients with systemic amyloidosis
with involvement of the larynx or patients not eligible for
systematic follow-up every 6–12 months. After a follow-up
period of 10 years patients without symptomatic amyloi-
dosis were dismissed.
Due to the observational nature of this longitudinal
study, according to Dutch law informed consent and per-
mission of the local ethics committee are not required.
Variables
The localization of the amyloid in the larynx and modalities
of surgery were described. During the follow-up period the
local progression and recurrence rate, number of revision
surgery procedures, progression to systemic amyloidosis,
and changes in voice were monitored yearly, except in the
first year when patients were monitored more frequently.
Local laryngeal evaluation and voice analysis
The larynx was evaluated by videolaryngostroboscopy
(digital video stroboscope, model 9100B, KayPentax,
Lincoln Park, NJ, USA) with a 90 Von Stuckrad telescope
(R. Wolf, Knittlingen, Germany). The voice was analyzed
with phonation time, phonetography (voice range profile),
GRBAS scoring system and Voice Handicap Index-30
(VHI-30). Phonation time and phonetography are parame-
ters to evaluate the voice [15]. The GRBAS scoring system
is a perceptual, subjective evaluation of the voice [16]. The
VHI-30 is an assessment of the subjective handicap of the
voice [17]. It ranges from 0 (no complaints) to a maximum
of 120. A change of more than 14 is significant in the
Dutch version of the VHI [17].
Systemic clinical evaluation
Systemic amyloidosis was made unlikely in each patient by
thorough clinical evaluation. A standard protocol was used
to evaluate heart, liver, kidney, bone marrow, and periph-
eral and autonomic nervous system [3, 5]. Systemic amy-
loidosis was looked for using biopsies of abdominal fat,
rectum or bone marrow, along with whole body 123I-la-
beled serum amyloid P component scintigraphy (123I-SAP
scan), a method used for imaging visceral amyloid deposits
[18].
Surgical treatment
As surgical modalities during suspension microlaryn-
goscopy, cold steel surgery, CO2 laser excision, a
microdebrider, or a combination of these techniques were
used. All patients underwent surgery under general anes-
thesia with orotracheal intubation or high frequency jet
ventilation. Planned staged interventions on each side of
the glottis with an interval of 3–6 months, to prevent
webbing, were counted as one single intervention and not
as two interventions.
Statistical analysis
Statistical analysis was performed using Graphpad Prism
version 5.04 for Windows, (Graphpad Software, San Diego
CA, USA). The Kaplan–Meier curve was used to calculate




Twenty-two patients with laryngeal amyloidosis were
referred to our tertiary center between 1994 and 2015.
Eighteen patients could be included. Median age of the 18
included patients (seven women and eleven men) was
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50 years at first presentation (range 21–77 years). Five
patients have already been reported in our initial report [3]
and were now re-evaluated after longer follow-up. Char-
acteristics of all patients are shown in Table 1.
Four patients were excluded. The first patient was lost
during follow-up. The second patient was excluded
because she was treated with postoperative irradiation after
initial surgery. The third patient presented for the first
evaluation 10 years after therapeutic suspension micro-
laryngoscopy elsewhere, and was not operated during fol-
low-up. The fourth was excluded because she did not
present with localized laryngeal amyloidosis, but multifo-
cal amyloidosis in the nasopharynx, the larynx and tra-
cheobronchial tree necessitating tracheotomy.
Localization of laryngeal amyloid
Patient characteristics are presented in Table 1. The sites
where amyloid in the larynx was found are displayed in
Tables 1 and 2. Twelve patients had bilateral deposition of
amyloid. Amyloid deposition pattern at initial presentation
was multifocal in four patients (Nos. 4, 5, 11 and 16) and
discretely unifocal in four patients (Nos. 6, 10, 14, and 15).
A striking observation was the fact that in some patients
(e.g. Nos. 5 and 16) recurrent amyloid bulk shifted from one
side to the other, or from one part of the larynx to another.
Detailed information of the initial distribution of amy-
loid could not be retrieved in the remaining patients. These
patients were referred to our center after the first diagnostic
endoscopy performed elsewhere.
Surgical treatment
The indications for surgery are listed in Tables 1 and 2. The
aim of surgery was either excision or debulking of the
amyloid deposits. Cold steel or CO2 laser excision was used
as surgical modality, in five cases supported by use of a
microdebrider. In one case (No. 18), a staged intervention
was performed for the left and right side of the glottis sep-
arately to prevent webbing. In two other cases with a planned
staged intervention (Nos. 4 and 15), the second intervention
was cancelled because of a good postoperative voice.
Investigation of systemic amyloidosis
None of the patients developed systemic amyloidosis dur-
ing follow-up. In three cases suspicion of systemic amy-
loidosis persisted despite negative first tests (case 3, 5, and
16). An elevated immunoglobulin free light chain serum
level (reference values: j\ 20.0 mg/l, k\ 32.0 mg/l) was
found in two patients (No. 3 and 5).
A 77-year-old man (No. 3) had an elevated serum level
of e¨ free light chain (52.0 mg/l) and a small e¨-positive
plasma cell clone in the bone marrow. He needed revision
surgery twice because of severe dysphonia and progression
of the local amyloid bulk in both vocal folds.
A 21-year-old man (No. 5) with amyloid deposits of the
left posterior faucial pillar, right oropharyngeal wall,
epiglottis and both false vocal folds, had an elevated serum
level of k free light chain (72.7 mg/l) and a small k-posi-
tive plasma cell clone in his bone marrow. He needed
revision surgery three times. The third revision was not for
amyloid but because of synechia of the false vocal folds
just superior of the anterior commissure.
A 41-year-old woman (No. 16) had not only AL amyloid
deposits in the left false vocal fold and the left subglottis,
but also in both eyelids and conjunctivae. She needed
revision surgery three times because of local progression of
the amyloid, leading to dyspnea and dysphonia.
Systemic amyloidosis was not found on repeated thor-
ough investigations, including 123I-SAP scintigraphy and
analysis of abdominal fat and rectum tissue, in any of the
three patients.
Revision surgery during follow-up
Follow-up of the individual patients is shown in Fig. 1a.
Median follow-up was 78 months (range 29–204 months).
Eleven patients needed revision surgery. Five of them
needed a second revision within 6 years after initial sur-
gical treatment (Fig. 1b). Two patients, No. 5 and 16,
needed a third revision 9 months and 6.3 years after the
second revision, respectively. One patient underwent his
first revision after 11 years of follow-up because of unex-
pected and rapidly progressive dysphonia and to rule out
malignancy (No. 14). At the last visit 12 of the 18 patients
still had clinically indolent residual amyloid without signs
of progression (Table 2; Fig. 1a).
Voice analysis
GRBAS score, phonetographic parameters, aerodynamic
values and VHI-30 were available only in a limited number
of cases as shown in Table 3. The numbers were too small
for statistic analysis. Phonetographic parameters and
aerodynamic parameters (phonation times on /a/, /s/ and /z/
) were available of 8 patients before initial surgery, 11 prior
to revision surgery and of 17 patients at the last visit. A
positive trend was present in GRBAS, melodic range, and
phonation times. In the few patients of whom VHI-30
values were present, there was a clinically significant
improvement.
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Table 1 Localization and
surgical data of the patients with
localized laryngeal amyloidosis
N Sex Age I. No Localization Indic Surgical modality Aim
SG FVF TVF Sub O BD Laser MD
1 F 68 IS – – B – – II, III B – – Ex
R1 – – L – – I, II, III L – – Ex
2 F 75 IS – – – B – III B – – Ex
3 M 77 IS – – L – – III, VI – L – Ex
R1 R – L – – I, III – L – Ex
R2 L L – – – I, II, III – L – Ex
4 M 54 IS-a – – B B – III L – – Db
R1 – – L L – III – L – Ex
5 M 21 IS B B – – a III – – – NA
R1 B B – – – I, III – B B Ex
R2 L R – – – I, III – B B Ex
R3 – B – – – III – B – Ex
6 M 53 IS R – – – – III – – – Ex
R1 R – – – – I, III – R R Ex
7 M 55 IS – R – – – III – R R Ex
8 M 55 IS B – – – – III – B B Ex
9 M 45 IS – – B – – III – R – Db
10 F 42 IS – – – B – III B – – Db
11 M 49 IS B B B – – III B – – Db
R1 – B – – – I – B – Db
R2 – B – – – I – B – Ex
12 M 72 IS – L – – – III L – – Db
13 F 51 IS – R – – – III R – – Ex
R1 R – – – III – R – Ex
14 F 40 IS – B – – – III B – – Ex
15 F 39 IS-a – – B B – III B – – Db
R1 – – B B – I, IV R – – Ex
16 F 41 IS – L B L b II, III B – – Db
R1 – L L L – I, II, III TVF FVF – Db
R2 – – – R – I, II, III – B – Ex
R3 – – B – I, II, III B Db
17 M 23 IS R R – – – III – R – Ex
R1 R R – – – V – R – Ex
R2 R R R – – I, II – R – Ex
18 M 49 IS-a – – B – – III L – – Db
IS-b III R – – Db
R1 – – B B – I, VI B – – Db
N patient number, I. no intervention number, Age age at presentation, Indic. indication for surgery, I pro-
gression of disease, II dyspnea, III dysphonia, IV aphonia, V dysphagia, VI suspected malignancy, Aim
surgical aim, SG supraglottic other than false vocal fold, FVF false vocal fold, TVF true vocal fold, sub
subglottis, O outside the larynx, BD blunt dissection, Laser CO2 laser, MD microdebrider, M male, F fe-
male, R right side, L left side, B bilateral, IS initial surgery, R1 first revision, R2 second revision, R3 third
revision, IS-a planned staged initial surgery, first stage, IS-b planned staged initial surgery, second stage, Ex
excision, NA not available, Db debulking, Patients number 8, 15–18 have been described earlier as patient
number 5, 3, 2,1, and 4, respectively, in Bartels et al. [3]
a Amyloid in oropharyx
b Amyloid in eyelids and conjunctivae
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Discussion
Long-term effectiveness of our surgical approach in
localized laryngeal amyloidosis was studied. This study is
the largest cohort study of protocol-based [3] monitoring of
patients with localized laryngeal amyloidosis having a
median follow-up of more than 5 years. Implicitly,
watchful waiting was performed in cases with residual
disease. Amyloid recurred locally in all patients after initial
surgery, but disease progression stopped after 7 years after
the last surgery in all but one of the patients. Eleven
patients needed revision surgery. Five patients needed a
second revision, two needed a third revision. Postoperative
voice of most patients, when recorded, was only mildly
affected. None of the patients developed systemic amy-
loidosis during follow-up.
Clinical follow-up by a laryngologist is based on
symptoms and signs. The cumulative follow-up of nearly
145 patient-years in this group of 18 patients showed
residual amyloid after first surgery in all patients. However,
a need for revision surgery was present in only two-thirds
of the patients within 4 years after initial surgery (Fig. 1b).
A need for a second revision surgery was seen in almost
half of the patients within 6 years after initial surgery. Two
patients needed a third revision surgery within 7 years,
respectively, after second surgery (Fig. 1b).
Presence of residual amyloid after more than 10 years
follow-up has been described [10–12, 19–21]. Need for
revision surgery after more than 10 years, as in patient No.
14 and 16, is rarely indicated [10, 17, 24]. Our data seem to
indicate that local progression of amyloid slows down after
6 years. This slowing-down of the disease may be caused
by exhaustion of the underlying clonal plasma cells. A
toxic effect on plasma cells of self-produced pre-amyloid
might play a role [1]. In none of the series comprising ten
or more patients with well-defined localized laryngeal
amyloidosis and documented follow-up longer than
5 years, revision surgery was necessary after more than
7 years [8, 9, 12, 22, 23]. Thus a laryngological follow-up
period of at least 7 years after the last surgical intervention
is recommended in this disease.
Because localized laryngeal AL amyloidosis is regarded
a benign disease, radical removal of all amyloid is not
indicated. Suspension microlaryngoscopy [6, 7, 9] using
cold instruments, CO2 laser and microdebrider are nowa-
days the surgical modalities of choice to treat laryngeal
amyloidosis.
Our approach [3] is somewhere in between a ‘‘minimal
excision technique’’ [9] and a rigorous debulking regimen
[6]. It is guided by both symptoms (dysphonia, dysphagia,
dyspnea) and signs (asymptomatic progression), as shown
in Table 2. Excision is preferred. Debulking is performed
instead of excision if voice, swallowing or breathing might
be affected by radical resection. A need for possible revi-
sion is assessed during regular yearly follow-up (after 3
and 6 months in the first postoperative year) or when
symptoms appear. Staged surgery per side is performed to
prevent anterior webbing. For small deposits or deposits in
Table 2 Amyloid localization












Subglottis 5 4 1 0 4
Glottis 8 6 1 1 5
False vocal
folds




5 4 3 0 4
Indications
Progression NA 8 5 1
Dyspnea 2 2 3 1
Dysphonia 15 7 3 2
Aphonia 0 1 0 0
Dysphagia 0 1 0 0
Possible
malignancy
1 1 0 0
Notice that patients can have amyloidosis or recurrence at more than one laryngeal area
NA not applicable
a Two patients had residual disease in two laryngeal regions
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the glottis, cold steel excision is favored. Excision with
CO2 laser is preferred for bulky amyloid in the subglottis
and supraglottis.
In older studies other surgical modalities have been
described such as an external approach to the larynx [10]
and total laryngectomy to remove the bulk of amyloid [11,
12]. The size and localization of amyloid sometimes
necessitated a tracheotomy [8, 19–21] or endoluminal
stents [8] to secure the airway. Fatal complications due to
cannula-related death [8, 24] or hemorrhage with asphyxia
[8] have been reported. Even a severe, recurrent,
transglottic, bilateral bulky amyloid can now be mastered
using multiple resections with CO2 laser and microdebrider
[17], thereby preventing total laryngectomy as salvage
surgery, as has been described in the past [12].
The main reason for surgical treatment and revision
surgery in the study group was dysphonia. This corre-
sponds with observations made in literature [6, 8, 9, 22].
The voice was impaired in more than 82 % initially,
although in only 44 % the amyloid was located in the
glottis. This discrepancy is explained by the observed
mechanical obstruction of a supraglottic amyloid bulk at
laryngostroboscopy. Such a bulk hampers formation of
harmonics. In our study the voice is only mildly affected at
the last visit. However, because of the observational nature
of our study insufficient quantitative data were available to
study a possible improvement of voice characteristics dis-
played in Table 3. Major limitations of this study were its
observational nature and, although one of world’s largest
series, the relatively small number of patients. Because of
the long time span of our study, some preoperative voice
characteristics were not available or not commonly known
by referring physicians at the time of diagnostic endoscopy.
This explains the lack of data on preoperative voice char-
acteristics in most of the patients.
Amyloid can be present in a multifocal pattern in the
larynx [23] or airways [22, 23]. It can even shift its location
within the larynx, as we observed during our surgical
interventions. We found multifocal and continuous
deposits spanning more than one part of the larynx. Con-
comitant localized amyloid deposits outside the larynx, as
in the eyelids (patient No. 12) or oropharynx (patient No.
2), have been reported in the nasopharynx [20], nasal sinus
[15], tongue [23], oropharynx [10], tonsils [9, 20] and
tracheobronchial tree [11, 12]. Two patients (No. 1 and No.
2) had a low grade plasma cell clone in the bone marrow.
The multifocal pattern of laryngeal amyloid deposition, the
concomitant multiple localizations outside the larynx, and
the presence of a plasma cell clone in bone marrow all
indicate that localized laryngeal amyloidosis is not really a
strictly localized disease, but a local manifestation of a
more widespread plasma cell dyscrasia.
Conclusion
Treatment of choice in local laryngeal amyloidosis is cal-
culated microlaryngeal surgery guided on symptoms and
signs. After initial microlaryngeal surgery, amyloid recur-
red locally in all patients. Two-thirds of all patients needed
revision surgery, half of them within 1 year after initial
surgery. A second or third revision for amyloid was nec-
essary in about 60 % of all patients within 6 years after the
last surgery. Postoperative voice was only mildly affected
Fig. 1 a Follow-up of all patients after initial surgical treatment of
localized laryngeal AL amyloid. For each individual patient (number
corresponds with Table 1) the time interval is displayed of first
symptoms (open triangle) to initial surgical treatment (t = 0) and
thereafter each surgical intervention (X) and duration of follow-up
(dotted line). At the end of each line is displayed the presence (closed
triangle) or absence (open circle) of amyloid residual disease as
observed at the last visit. b Need for revision surgery after last
surgical treatment of localized laryngeal amyloid. Kaplan–Meier
curves show the need for first revision surgery (open boxes, N = 18),
for second revision surgery (closed circles, N = 11), and for third
revision surgery (open triangles, N = 5) during 10 years after the last
surgical procedure. Subjects censored at the end of their follow-up are
located on a horizontal part of the curves. Subjects who had that
revision surgery as event are located on top of vertical parts of the
curves. The vertical axis shows the actuarial risk of revision surgery
as percentage of all patients who had been treated with surgery. The
dotted line represents the 50 % risk of revision surgery
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in most patients. Follow-up of 7 years after last surgery is
recommended because progression of the disease usually
comes to a stop after 7 years.
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